Microalbuminuria in Type 2 Diabetics: an Important, Overlooked Cardiovascular Risk Factor

Overview

Journal J Clin Hypertens (Greenwich)

Specialty Cardiology & Vascular Diseases

Date 2004 Mar 11

PMID 15010646

Citations 21

Authors

Matthew R Weir

Affiliations

Soon will be listed here.

Abstract

The presence of microalbumin in the urine of persons with type 2 diabetes is perhaps the most important early signal heralding the onset of systemic vasculopathy and associated target organ damage to the brain, the heart, and the kidneys. It is easily measured and, unfortunately, frequently overlooked as a screening tool in clinical medicine. If present, it identifies patients at risk for early cardiovascular death and progressive renal disease. Microalbuminuria also identifies patients who need more rigorous cardiovascular risk management, especially more intensive blood pressure control, preferably below 130/80 mm Hg, and strict attention to glycemic control and lipid levels. Therapeutic strategies to facilitate better blood pressure control and reduce microalbuminuria likely will prove to be the most effective way to retard not only the progression of renal disease but also cardiovascular disease. Consequently, the identification and normalization of urine microalbumin excretion should be an important consideration in patients with diabetes.

Citing Articles

Comparison of Clinical Outcomes of Implantation of Foldable Hydrophobic Acrylic Intraocular Lens With and Without Heparin Surface Modification in Indian Diabetic Patients.

Kumari D, Simakurthy S, Sharma N, Titiyal J, Kumar A, Chawla R Cureus. 2024; 16(3):e56855.

PMID: 38659517 PMC: 11040019. DOI: 10.7759/cureus.56855.

Prevalence of Microalbuminuria Among Diabetes Patients in Africa: A Systematic Review and Meta-Analysis.

Mohammed O, Alemayehu E, Bisetegn H, Debash H, Gedefie A, Ebrahim H Diabetes Metab Syndr Obes. 2023; 16:2089-2103.

PMID: 37457109 PMC: 10349577. DOI: 10.2147/DMSO.S409483.

Exploring the Correlates of Hematological Parameters With Early Diabetic Nephropathy in Type 2 Diabetes Mellitus.

Chollangi S, Rout N, Satpathy S, Panda B, Patro S Cureus. 2023; 15(5):e39778.

PMID: 37398707 PMC: 10312475. DOI: 10.7759/cureus.39778.

Microalbuminuria and mortality in individuals with coronary heart disease: A meta-analysis of a prospective study.

Govardi E, Yulianda D, Habib F, Pakpahan C Indian Heart J. 2023; 75(4):229-235.

PMID: 37207828 PMC: 10421992. DOI: 10.1016/j.ihj.2023.05.006.

The Relationship Between Depression and Multifactorial Control and Microvascular Complications in Vietnamese with Type 2 Diabetes Mellitus Aged 30-60 Years.

Le T, Huy Duong H, Thi Nguyen L, Phi Thi Nguyen N, Nguyen S, Van Ngo M Diabetes Metab Syndr Obes. 2022; 15:1185-1195.

PMID: 35464259 PMC: 9031987. DOI: 10.2147/DMSO.S354443.

References

Gerstein H, Mann J, Yi Q, Zinman B, Dinneen S, Hoogwerf B . Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA. 2001; 286(4):421-6. DOI: 10.1001/jama.286.4.421. View

Sowers J, Epstein M, Frohlich E . Diabetes, hypertension, and cardiovascular disease: an update. Hypertension. 2001; 37(4):1053-9. DOI: 10.1161/01.hyp.37.4.1053. View

Valmadrid C, Klein R, Moss S, Klein B . The risk of cardiovascular disease mortality associated with microalbuminuria and gross proteinuria in persons with older-onset diabetes mellitus. Arch Intern Med. 2000; 160(8):1093-100. DOI: 10.1001/archinte.160.8.1093. View

Brenner B, Cooper M, de Zeeuw D, Keane W, Mitch W, Parving H . Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001; 345(12):861-9. DOI: 10.1056/NEJMoa011161. View

Tuttle K, Puhlman M, Cooney S, Short R . Urinary albumin and insulin as predictors of coronary artery disease: An angiographic study. Am J Kidney Dis. 1999; 34(5):918-25. DOI: 10.1016/S0272-6386(99)70051-X. View

Fogari R, Preti P, Zoppi A, Rinaldi A, Corradi L, Pasotti C . Effects of amlodipine fosinopril combination on microalbuminuria in hypertensive type 2 diabetic patients. Am J Hypertens. 2002; 15(12):1042-9. DOI: 10.1016/s0895-7061(02)03017-0. View

Jafar T, Stark P, Schmid C, Landa M, Maschio G, Marcantoni C . Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease. Kidney Int. 2001; 60(3):1131-40. DOI: 10.1046/j.1523-1755.2001.0600031131.x. View

Ravid M, Lang R, Rachmani R, Lishner M . Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. A 7-year follow-up study. Arch Intern Med. 1996; 156(3):286-9. View

Remuzzi G, Bertani T . Pathophysiology of progressive nephropathies. N Engl J Med. 1998; 339(20):1448-56. DOI: 10.1056/NEJM199811123392007. View

10.

Forsblom C, Groop P, Ekstrand A, Totterman K, Sane T, Saloranta C . Predictors of progression from normoalbuminuria to microalbuminuria in NIDDM. Diabetes Care. 1998; 21(11):1932-8. DOI: 10.2337/diacare.21.11.1932. View

11.

Just A, Ehmke H, Toktomambetova L, Kirchheim H . Dynamic characteristics and underlying mechanisms of renal blood flow autoregulation in the conscious dog. Am J Physiol Renal Physiol. 2001; 280(6):F1062-71. DOI: 10.1152/ajprenal.2001.280.6.F1062. View

12.

Gall M, Borch-Johnsen K, Hougaard P, Nielsen F, Parving H . Albuminuria and poor glycemic control predict mortality in NIDDM. Diabetes. 1995; 44(11):1303-9. DOI: 10.2337/diab.44.11.1303. View

13.

Mogensen C, Keane W, BENNETT P, Jerums G, Parving H, Passa P . Prevention of diabetic renal disease with special reference to microalbuminuria. Lancet. 1995; 346(8982):1080-4. DOI: 10.1016/s0140-6736(95)91747-0. View

14.

Brouwer C, Stehouwer C, Smulders Y . Rapid progression of albumin excretion is an independent predictor of cardiovascular mortality in patients with type 2 diabetes and microalbuminuria. Diabetes Care. 2001; 24(12):2097-101. DOI: 10.2337/diacare.24.12.2097. View

15.

Heeg J, de Jong P, VAN DER HEM G, de Zeeuw D . Efficacy and variability of the antiproteinuric effect of ACE inhibition by lisinopril. Kidney Int. 1989; 36(2):272-9. DOI: 10.1038/ki.1989.190. View

16.

Bakris G, Williams M, Dworkin L, ELLIOTT W, Epstein M, Toto R . Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis. 2000; 36(3):646-61. DOI: 10.1053/ajkd.2000.16225. View

17.

Borch-Johnsen K, Feldt-Rasmussen B, Strandgaard S, Schroll M, Jensen J . Urinary albumin excretion. An independent predictor of ischemic heart disease. Arterioscler Thromb Vasc Biol. 1999; 19(8):1992-7. DOI: 10.1161/01.atv.19.8.1992. View

18.

Lewis E, Hunsicker L, Clarke W, Berl T, Pohl M, Lewis J . Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001; 345(12):851-60. DOI: 10.1056/NEJMoa011303. View

19.

Pegoraro A, Peracha W, Hasnain M, Ranginwala N, Shaykh M, Singh A . Evaluation of a new fluorescent dye method to measure urinary albumin in lieu of urinary total protein. Am J Kidney Dis. 2000; 35(4):739-44. DOI: 10.1016/s0272-6386(00)70023-0. View

20.

Griffin K, Picken M, Bakris G, Bidani A . Comparative effects of selective T- and L-type calcium channel blockers in the remnant kidney model. Hypertension. 2001; 37(5):1268-72. DOI: 10.1161/01.hyp.37.5.1268. View